Donald Cameron

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: SCIENCE ADVANCES. 2023;9(41):eadg5109
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription
Cameron DP; Grosser J; Ladigan S; Kuzin V; Iliopoulou E; Wiegard A; Benredjem H; Jackson K; Liffers ST; Lueong S; Cheung PF; Vangala D; Pohl M; Viebahn R; Teschendorf C; Wolters H; Usta S; Geng K; Kutter C; Arsenian-Henriksson M; Siveke JT; Tannapfel A; Schmiegel W; Hahn SA; Baranello L
Article: STAR PROTOCOLS. 2022;3(3):101581
TOP1 CAD-seq: A protocol to map catalytically engaged topoisomerase 1 in human cells
Kuzin V; Wiegard A; Cameron DP; Baranello L
Article: CANCER RESEARCH COMMUNICATIONS. 2022;2(3):182-201
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner
Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickstrom M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson L-G
Article: MOLECULAR CELL. 2022;82(1):140-158.e12
MYC assembles and stimulates topoisomerases 1 and 2 in a "topoisome"
Das SK; Kuzin V; Cameron DP; Sanford S; Jha RK; Nie Z; Rosello MT; Holewinski R; Andresson T; Wisniewski J; Natsume T; Price DH; Lewis BA; Kouzine F; Levens D; Baranello L
Article: MOLECULAR CELL. 2021;81(24):5007-5024.e9
Topoisomerase 1 activity during mitotic transcription favors the transition from mitosis to G1
Wiegard A; Kuzin V; Cameron DP; Grosser J; Ceribelli M; Mehmood R; Ballarino R; Valant F; Grochowski R; Karabogdan I; Crosetto N; Lindqvist A; Bizard AH; Kouzine F; Natsume T; Baranello L
Article: PLOS PATHOGENS. 2021;17(9):e1009954
The Epstein-Barr virus deubiquitinating enzyme BPLF1 regulates the activity of topoisomerase II during productive infection
Li J; Nagy N; Liu J; Gupta S; Frisan T; Hennig T; Cameron DP; Baranello L; Masucci MG
Article: PLOS GENETICS. 2021;17(9):e1009763
Deficiency of Polη in Saccharomyces cerevisiae reveals the impact of transcription on damage-induced cohesion
Wu P-S; Grosser J; Cameron DP; Baranello L; Strom L
Article: METHODS IN MOLECULAR BIOLOGY. 2021;2318:161-185
Analysis of Myc Chromatin Binding by Calibrated ChIP-Seq Approach.
Cameron DP; Kuzin V; Baranello L
Article: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY. 2020;8:568
rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461
Son J; Hannan KM; Poortinga G; Hein N; Cameron DP; Ganley ARD; Sheppard KE; Pearson RB; Hannan RD; Sanij E
Article: CANCER DISCOVERY. 2019;9(8):1036-1049
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study
Khot A; Brajanovski N; Cameron DP; Hein N; Maclachlan KH; Sanij E; Lim J; Soong J; Link E; Blombery P; Thompson ER; Fellowes A; Sheppard KE; McArthur GA; Pearson RB; Hannan RD; Poortinga G; Harrison SJ
Article: COMMUNICATIONS BIOLOGY. 2019;2:39
Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation
Diesch J; Bywater MJ; Sanij E; Cameron DP; Schierding W; Brajanovski N; Son J; Sornkom J; Hein N; Evers M; Pearson RB; McArthur GA; Ganley ARD; O'Sullivan JM; Hannan RD; Poortinga G
Article: INTERNATIONAL JOURNAL OF CANCER. 2018;142(10):2139-2152
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Article: BLOOD. 2017;129(21):2882-2895
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
Hein N; Cameron DP; Hannan KM; Nguyen N-YN; Fong CY; Sornkom J; Wall M; Pavy M; Cullinane C; Diesch J; Devlin JR; George AJ; Sanij E; Quin J; Poortinga G; Verbrugge I; Baker A; Drygin D; Harrison SJ; Rozario JD; Powell JA; Pitson SM; Zuber J; Johnstone RW; Dawson MA; Guthridge MA; Wei A; McArthur GA; Pearson RB; Hannan RD
Article: NATURE COMMUNICATIONS. 2017;8:14581-10
Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene
Lefebure M; Tothill RW; Kruse E; Hawkins ED; Shortt J; Matthews GM; Gregory GP; Martin BP; Kelly MJ; Todorovski I; Doyle MA; Lupat R; Li J; Schroeder J; Wall M; Craig S; Poortinga G; Cameron D; Bywater M; Kats L; Gearhart MD; Bardwell VJ; Dickins RA; Hannan RD; Papenfuss AT; Johnstone RW
Article: PLOS NEGLECTED TROPICAL DISEASES. 2017;11(3):e0005432
Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis
Kerry LE; Pegg EE; Cameron DP; Budzak J; Poortinga G; Hannan KM; Hannan RD; Rudenko G
Article: CLINICAL CANCER RESEARCH. 2016;22(22):5539-5552
The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Article: ONCOTARGET. 2016;7(31):49800-49818
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
Quin J; Chan KT; Devlin JR; Cameron DP; Diesch J; Cullinane C; Ahern J; Khot A; Hein N; George AJ; Hannan KM; Poortinga G; Sheppard KE; Khanna KK; Johnstone RW; Drygin D; McArthur GA; Pearson RB; Sanij E; Hannan RD
Article: GENOME RESEARCH. 2015;25(2):201-212
A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes
Sanij E; Diesch J; Lesmana A; Poortinga G; Hein N; Lidgerwood G; Cameron DP; Ellul J; Goodall GJ; Wong LH; Dhillon AS; Hamdane N; Rothblum LI; Pearson RB; Haviv I; Moss T; Hannan RD
Journal article: PIGMENT CELL AND MELANOMA RESEARCH. 2014;27(4):590-600
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(18):3936-3944
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB

Alla övriga publikationer

Meeting abstract: CANCER RESEARCH. 2017;77:b23
Inhibition of ribosomal RNA synthesis as a new therapeutic approach to treat advanced prostate cancer
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Meeting abstract: CANCER RESEARCH. 2016;76:5181
Dual inhibition of RNA Pol I transcription and PIM kinase as a new therapy to treat prostate cancer
Rebello RJ; Kusnadi E; Cameron D; Lesmana A; Drygin D; Clark AK; Porter L; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2016;61:s167
The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer
Rebello R; Kusnadi E; Cameron D; Pearson H; Lesmana A; Devlin J; Drygin D; Clark A; Porter L; Pedersen J; Sandhu S; Risbridger G; Pearson R; Hannan R; Furic L
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2016;61:s134-s135
A novel role for Top2α as a mediator of resistance to ribosomal DNA transcription inhibition
Cameron D; Sanij E; Bywater M; Hein N; Lim J; McArthur G; Poortinga G; Hannan R
Meeting abstract: MOLECULAR CANCER RESEARCH. 2015;13:a31
Elucidating mechanisms that cooperate with the therapeutic inhibition of RNA polymerase I to treat MYC-driven hematological malignancies
Poortinga G; Diesch J; Sanij E; Hein N; Sornkum J; Cameron D; Bywater MJ; Johnstone R; Drygin D; O'Brien S; Pearson RB; McArthur GA; Hannan RD
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(15):e280-e281
A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM).
Harrison SJ; Khot A; Brajanovski N; Cameron D; Hein N; McArthur GA; Lim JKC; O'Brien S; Ryckman DM; Yu GI; Link E; Donohoe C; Snowden A; Kuru N; Hannan R
Meeting abstract: CANCER RESEARCH. 2014;74(19):2735
Multi-point targeting of the synthetic lethal interactions between Myc, ribosome biogenesis and ribosome function cooperates to treat B-cell lymphoma
Pearson RB; Devlin JR; Hannan KM; Hein N; Bywater MJ; Poortinga G; Cameron D; Drygin D; O'Brien S; Cullinane C; McArthur GA; Hannan RD
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2014;50:s185
Targeting MYC-driven growth and proliferation in prostate cancer
Rebello R; Drygin D; Cameron D; Risbridger GP; Pearson RB; Hannan RD; Furic L
Review: BIOCHIMICA ET BIOPHYSICA ACTA: INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS. 2014;1842(6):802-816
Targeting the nucleolus for cancer intervention
Quin JE; Devlin JR; Cameron D; Hannan KM; Pearson RB; Hannan RD
Meeting abstract: CANCER RESEARCH. 2013;73:pr16
Combined inhibition of ribosome function and ribosomal RNA gene transcription cooperate to delay relapse and extend survival in MYC-driven tumors
Hannan R; Devlin J; Hannan K; Hein N; Bywater M; Poortinga G; Cameron D; Drygin D; Cullinane C; O'Brien S; McArthur G; Pearson R

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI